The Recall Desk
ModerateFDA (Drugs)·D-0337-2025·Announced 2025-04-16

Lacosamide Tablets 50mg Recalled for CGMP Manufacturing Deviations

Glenmark Pharmaceuticals Inc., USA is voluntarily recalling Lacosamide Tablets 50mg due to Current Good Manufacturing Practice (CGMP) deviations. The recall affects specific lots distributed nationwide.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: The recall is FDA Class II for CGMP deviations without any reported illnesses or injuries. Under the rubric, Class II recalls without hospitalization reports are typically Moderate severity.

Plain-English summary

Glenmark Pharmaceuticals Inc., USA is voluntarily recalling Lacosamide Tablets, 50mg, in 60-count bottles (NDC# 68462-678-60) due to Current Good Manufacturing Practice (CGMP) deviations identified during manufacturing. The affected lots are #17240221 and #17240222, both with expiration date January 2026.

The product was distributed nationwide in the United States. Lacosamide is a prescription oral medication used to treat seizures. The FDA has classified this recall as Class II.

Patients currently taking Lacosamide from affected lots should contact their healthcare provider or pharmacist before stopping the medication. Healthcare providers and patients should report any adverse events to the FDA's MedWatch program.

The recalled product

Product
LACOSAMIDE (LACOSAMIDE)
Brand
LACOSAMIDE
Manufacturer
Glenmark Pharmaceuticals Inc., USA
Hazard
  • cgmp-deviation
  • manufacturing-defect

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (3)

  • Lot # 17240221
  • exp. date Jan-26 17240222
  • exp. date Jan-26

UPCs (4)

  • 0368462681602
  • 0368462679609
  • 0368462678602
  • 0368462680605

Distribution

Distributed nationwide across the United States.